Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Cadrenal Therapeutics, Inc. ( (CVKD) ) has provided an announcement.
On December 23, 2025, Cadrenal Therapeutics, Inc. filed a prospectus supplement with the U.S. Securities and Exchange Commission to continue using its at-the-market equity offering program, allowing the company to offer and sell up to an additional $1,770,028 of its common stock through H.C. Wainwright & Co. as sales agent. This supplemental capacity, which follows approximately $10.0 million of stock already sold under the existing March 11, 2024 agreement, provides Cadrenal with flexible, discretionary access to incremental capital, while specifying parameters such as trading periods, volume limits, and minimum prices, and compensating H.C. Wainwright with a 3% fee on gross sales, with no obligation for the company to sell any shares and the ability for either party to terminate the arrangement under agreed conditions.
The most recent analyst rating on (CVKD) stock is a Buy with a $45.00 price target. To see the full list of analyst forecasts on Cadrenal Therapeutics, Inc. stock, see the CVKD Stock Forecast page.
Spark’s Take on CVKD Stock
According to Spark, TipRanks’ AI Analyst, CVKD is a Underperform.
The overall score reflects significant financial challenges, including ongoing losses and no revenue generation, which weigh heavily on the company’s outlook. Technical indicators suggest limited momentum, while valuation metrics highlight difficulties in assessing the stock’s fair value. Despite a positive corporate development with the appointment of a new Chief Medical Officer, the fundamental financial weaknesses remain the dominant concern.
To see Spark’s full report on CVKD stock, click here.
More about Cadrenal Therapeutics, Inc.
Cadrenal Therapeutics, Inc. is a Delaware-incorporated company that issues common stock and accesses U.S. capital markets, using at-the-market equity offering programs to raise funds for its operations and corporate purposes.
Average Trading Volume: 41,780
Technical Sentiment Signal: Sell
Current Market Cap: $16.62M
Find detailed analytics on CVKD stock on TipRanks’ Stock Analysis page.